Introduction: Hedysarum Multijugum Maxim (HMM), a Chinese traditional medicine, exerts antitumor effects and has been extensively studied for its potential to treat cancer in recent years. Clinical research has shown that HMM can control hepatocellular cancer, but the exact molecular mechanism is unclear. Methods: To identify the principal bioactive constituents of HMM and their corresponding targets, we constructed a protein-protein interaction (PPI) network. Second, the Cytoscape software was utilized to delineate the relationships among drugs, active components, targets, and illnesses. Gene ontology analysis and Kyoto Encyclopedia of Genes and Genomes (KEGG) enrichment analysis using the clusterProfiler tools on the DAVID platform and the Bioconductor package in R. Molecular docking was performed on the PubChem database, whereas the AutoDock, and PyMOL software were utilized to explore the binding affinity of the primary targets and active molecules. Results: Network pharmacology and molecular docking analyses identified six key active constituents of HMM: quercetin, kaempferol, formononetin, isorhamnetin, calycosin, and 7-O-methylisomucronulatol. It was predicted that this herb can modulate the expression of several genes, including TP53, AKT1, MYC, CASP3, VEGFA, EGFR, HIF1A, ESR1, CCND1, and PTGS2. Conclusion: HMM has potential therapeutic effects on the liver cancer. This study provides important insights regarding the methods for investigating HMM in the treatment of hepatocellular cancer.

1.
Nguyen
ST
,
Huynh
KL
,
Nguyen
HL-T
,
Nguyen Thi Thanh
M
,
Nguyen Trung
N
,
Nguyen Xuan
H
, et al
.
Hopea odorata extract inhibits hepatocellular carcinoma via induction of caspase-dependent apoptosis
.
Onco Targets Ther
.
2017
;
10
:
5765
74
.
2.
Rumgay
H
,
Arnold
M
,
Ferlay
J
,
Lesi
O
,
Cabasag
CJ
,
Vignat
J
, et al
.
Global burden of primary liver cancer in 2020 and predictions to 2040
.
J Hepatol
.
2022
;
77
(
6
):
1598
606
.
3.
Yang
J
,
Pan
G
,
Guan
L
,
Liu
Z
,
Wu
Y
,
Liu
Z
, et al
.
The burden of primary liver cancer caused by specific etiologies from 1990 to 2019 at the global, regional, and national levels
.
Cancer Med
.
2022
;
11
(
5
):
1357
70
.
4.
Siegel
RL
,
Miller
KD
,
Jemal
A
.
Cancer statistics, 2019
.
CA Cancer J Clin
.
2019
,
69
(
1
):
7
34
,
5.
Maki
H
,
Hasegawa
K
.
Advances in the surgical treatment of liver cancer
.
Biosci Trends
.
2022
;
16
(
3
):
178
88
.
6.
Zhang
Z
,
Chong
W
,
Xie
X
,
Liu
Y
,
Shang
L
,
Li
L
.
Hedysarum multijugum Maxim treats ulcerative colitis through the PI3K-AKT and TNF signaling pathway according to network pharmacology and molecular docking
.
Ann Transl Med
.
2022
;
10
(
20
):
1132
.
7.
Ji
H
,
Lou
X
,
Jiao
J
,
Li
Y
,
Dai
K
,
Jia
X
.
Preliminary structural characterization of selenium nanoparticle composites modified by astragalus polysaccharide and the cytotoxicity mechanism on liver cancer cells
.
Molecules
.
2023
;
28
(
4
):
1561
.
8.
Xia
LJ
,
Zhang
LM
,
Yang
K
,
Chen
T
,
Ye
XW
,
Yan
ZJ
.
The pharmacological mechanism of xiyanping injection for the treatment of novel coronavirus pneumonia (COVID-19): based on network pharmacology strategy
.
Evid Based Complement Alternat Med
.
2022
;
2022
:
9152201
.
9.
Xu
J
,
Wang
F
,
Guo
J
,
Xu
C
,
Cao
Y
,
Fang
Z
,
Wang
Q
.
Pharmacological mechanisms underlying the neuroprotective effects of Alpinia oxyphylla Miq. on Alzheimer’s Disease
.
Int J Mol Sci
.
2020
;
21
(
6
):
2071
.
10.
Muthuramalingam
P
,
Govindasamy
R
,
Venkidasamy
B
,
Krishnan
M
,
Shin
H
.
Network pharmacology: a systems perspective possible underpinning approach for oral cancer treatment
.
Daru
.
2023
;
31
(
2
):
273
5
.
11.
Ru
J
,
Li
P
,
Wang
J
,
Zhou
W
,
Li
B
,
Huang
C
, et al
.
TCMSP: a database of systems pharmacology for drug discovery from herbal medicines
.
J Cheminform
.
2014
;
6
(
1
):
13
.
12.
Xu
HY
,
Zhang
YQ
,
Liu
ZM
,
Chen
T
,
Lv
CY
,
Tang
SH
, et al
.
ETCM: an encyclopaedia of traditional Chinese medicine
.
Nucleic Acids Res
.
2019
;
47
(
D1
):
D976
82
.
13.
Szklarczyk
D
,
Gable
AL
,
Lyon
D
,
Junge
A
,
Wyder
S
,
Huerta-Cepas
J
, et al
.
STRING v11: protein-protein association networks with increased coverage, supporting functional discovery in genome-wide experimental datasets
.
Nucleic Acids Res
.
2019
;
47
(
D1
):
D607
13
.
14.
Safran
M
,
Dalah
I
,
Alexander
J
,
Rosen
N
,
Iny Stein
T
,
Shmoish
M
, et al
.
GeneCards Version 3: the human gene integrator
.
Database
.
2010
;
2010
:
baq020
.
15.
UniProt Consortium
.
UniProt: the universal protein knowledgebase in 2023
.
Nucleic Acids Res
.
2023
;
51
(
D1
):
D523
31
.
16.
Berman
HM
,
Westbrook
J
,
Feng
Z
,
Gilliland
G
,
Bhat
TN
,
Weissig
H
, et al
.
The protein data bank
.
Nucleic Acids Res
.
2000
;
28
(
1
):
235
42
.
17.
Wang
Y
,
Suzek
T
,
Zhang
J
,
Wang
J
,
He
S
,
Cheng
T
. et al
.
PubChem BioAssay: 2014 update
.
Nucleic Acids Res
.
2014
;
42
(
Database issue
):
1075
82
.
18.
Chen
Y
,
Wang
C
,
Zhang
G
,
Liu
W
,
Bian
H
.
Systematic elucidation of the pharmacological mechanisms of Hedysarum Multijugum Maxim for treating rhinitis via network
.
Phytomedicine Plus
.
2022
;
2
(
4
):
100341
.
19.
The Gene Ontology Consortium
.
The gene Ontology resource: 20 years and still GOing strong
.
Nucleic Acids Research
.
2018
;
47
(
D1
):
D330
8
.
20.
Yu
G
,
Wang
LG
,
Han
Y
,
He
QY
.
clusterProfiler: an R package for comparing biological themes among gene clusters
.
OMICS
.
2012
;
16
(
5
):
284
7
.
21.
Lee
JH
,
Ahn
J
,
Kim
JW
,
Lee
SG
,
Kim
HP
.
Flavonoids from the aerial parts of Houttuynia cordataattenuate lung inflammation in mice
.
Arch Pharm Res
.
2015
;
38
(
7
):
1304
11
.
22.
Rani
VU
.
Antiproliferative activity of quercetin on HepG2 cell line induced liver cancer in rats
.
World J Pharm Pharm Sci
.
2017
;
1138
55
.
23.
Zhao
X
,
Wang
J
,
Deng
Y
,
Liao
L
,
Zhou
M
,
Peng
C
, et al
.
Quercetin as a protective agent for liver diseases: a comprehensive descriptive review of the molecular mechanism
.
Phytother Res
.
2021
;
35
(
9
):
4727
47
.
24.
Zhu
G
,
Liu
X
,
Li
H
,
Yan
Y
,
Hong
X
,
Lin
Z
, et al
.
Kaempferol inhibits proliferation, migration and invasion of liver cancer HepG2 cells by down-regulation of microRNA-21
.
Int J Immunopathol Pharmacol
.
2018
:
32
:
2058738418814341
.
25.
Sharma
N
,
Biswas
S
,
Al-Dayan
N
,
Alhegaili
AS
,
Sarwat
M
.
Antioxidant role of kaempferol in prevention of hepatocellular carcinoma
.
Antioxidants
.
2021
;
10
(
9
):
1419
.
26.
Meng
J
,
Ai
XY
,
Lei
YY
,
Zhong
W
,
Qian
B
,
Qiao
K
, et al
.
USP5 promotes epithelial-mesenchymal transition by stabilizing SLUG in hepatocellular carcinoma
.
Theranostics
.
2019
;
9
(
2
):
573
87
.
27.
Teng
BS
,
Lu
YH
,
Wang
ZT
,
Tao
XY
,
Wei
DZ
.
In vitro anti-tumor activity of isorhamnetin isolated from Hippophae rhamnoides L. against BEL-7402 cells
.
Pharmacol Res
.
2006
;
54
(
3
):
186
94
.
28.
Lee
JH
,
Ahn
J
,
Kim
JW
,
Lee
SG
,
Kim
HP
.
Flavonoids from the aerial parts of Houttuynia cordata attenuate lung inflammation in mice
.
Arch Pharm Res
.
2015
;
38
(
7
):
1304
11
.
29.
Liu
Y
,
Wang
F
,
Yan
G
,
Tong
Y
,
Guo
W
,
Li
S
, et al
.
CPT1A loss disrupts BCAA metabolism to confer therapeutic vulnerability in TP53-mutated liver cancer
.
Cancer Lett
.
2024
;
595
:
217006
.
30.
Yao
J
,
Wang
XP
,
Yang
J
,
Yang
Z
,
Zhang
ZY
.
SCF-FBXL8 contributes to liver metastasis and stem-cell-like features in colorectal cancer cells by mediating ubiquitination and degradation of TP53
.
Clin Transl Med
.
2023
;
13
(
3
):
e1208
.
31.
Sun
W
,
Sun
Q
,
Zhong
A
,
Lyne
AM
,
Huang
D
,
Han
F
, et al
.
TP53 mutation is enriched in colorectal cancer liver metastasis in the context of polyclonal seeding
.
Pathol Res Pract
.
2022
;
236
:
153958
.
32.
Ge
Y
,
Xiao
B
,
Zhao
R
,
Li
B
,
Yang
S
,
He
KF
, et al
.
CARMIL1 regulates liver cancer cell proliferation by activating the ERK/mTOR pathway through the TRIM27/p53 axis
.
International immunopharmacology
.
2024
;
134
:
112139
.
33.
Thng
DKH
,
Hooi
L
,
Toh
CCM
,
Lim
JJ
,
Rajagopalan
D
,
Syariff
IQC
, et al
.
Histone-lysine N-methyltransferase EHMT2 (G9a) inhibition mitigates tumorigenicity in Myc-driven liver cancer
.
Mol Oncol
.
2023
;
17
(
11
):
2275
94
.
34.
Bakiri
L
,
Hasenfuss
SC
,
Guío-Carrión
A
,
Thomsen
MK
,
Hasselblatt
P
,
Wagner
EF
.
Liver cancer development driven by the AP-1/c-Jun∼Fra-2 dimer through c-Myc
.
Proc Natl Acad Sci U S A
.
2024
;
121
(
18
):
e2404188121
.
35.
Sim
DY
,
Lee
H-J
,
Ahn
C-H
,
Park
J
,
Park
SY
,
Kil
BJ
, et al
.
Negative regulation of CPSF6 suppresses the warburg effect and angiogenesis leading to tumor progression via c-myc signaling network: potential therapeutic target for liver cancer therapy
.
Int J Biol Sci
.
2024
;
20
(
9
):
3442
60
.
36.
Ma
J
,
Mo
J
,
Feng
Y
,
Wang
L
,
Jiang
H
,
Li
J
, et al
.
Combination of transcriptomic and proteomic approaches helps unravel the mechanisms of luteolin in inducing liver cancer cell death via targeting AKT1 and SRC
.
Front Pharmacol
.
2024
;
15
:
1450847
.
37.
Tian
L-Y
,
Smit
DJ
,
Popova
NV
,
Horn
S
,
Velasquez
LN
,
Huber
S
, et al
.
All three AKT isoforms can upregulate oxygen metabolism and lactate production in human hepatocellular carcinoma cell lines
.
Int J Mol Sci
.
2024
;
25
(
4
):
2168
.
38.
Pan
R
,
Zhao
Z
,
Xu
D
,
Li
C
,
Xia
Q
.
GPX4 transcriptionally promotes liver cancer metastasis via GRHL3/PTEN/PI3K/AKT axis
.
Transl Res
.
2024
;
271
:
79
92
.
39.
Li
S
,
Hao
L
,
Deng
J
,
Zhang
J
,
Hu
X
.
Coptidis rhizoma and evodiae fructus against lipid droplet deposition in nonalcoholic fatty liver disease-related liver cancer by AKT
.
Chem Biol Drug Des
.
2023
;
102
(
4
):
828
42
.
40.
Lan
T
,
Wang
J
,
Zeng
RH
,
Gao
C
,
Liu
X
,
Luo
L
, et al
.
Therapeutic targets and molecular mechanisms of Huangqin decoction in liver cancer: a network pharmacology and molecular docking approach
.
J Herb Med
.
2024
;
43
:
100822
.
41.
Lourenco
C
,
Resetca
D
,
Redel
C
,
Lin
P
,
MacDonald
AS
,
Ciaccio
R
, et al
.
MYC protein interactors in gene transcription and cancer
.
Nat Rev Cancer
.
2021
;
21
(
9
):
579
91
.
42.
Han
R
,
Yang
H
,
Lu
L
,
Lin
L
.
Tiliroside as a CAXII inhibitor suppresses liver cancer development and modulates E2Fs/Caspase-3 axis
.
Sci Rep
.
2021
;
11
(
1
):
8626
11
.
43.
Peach
CJ
,
Mignone
VW
,
Arruda
MA
Alcobia
DC
,
Hill
SJ
Kilpatrick
LE
, et al
.
Molecular pharmacology of VEGF-A isoforms: binding and signalling at VEGFR2
.
Int J Mol Sci
.
2018
;
19
(
4
):
1264
.
44.
Lin
J
,
Cao
S
,
Wang
Y
,
Hu
Y
,
Liu
H
,
Li
J
, et al
.
Long non-coding RNA UBE2CP3 enhances HCC cell secretion of VEGFA and promotes angiogenesis by activating ERK1/2/HIF-1α/VEGFA signalling in hepatocellular carcinoma
.
J Exp Clin Cancer Res
.
2018
;
37
(
1
):
113
.
45.
Wang
Q
,
Zhu
Y
,
Pei
J
.
Targeting EGFR with molecular degraders as a promising strategy to overcome resistance to EGFR inhibitors
.
Future Med Chem
.
2024
;
16
(
18
):
1923
44
.
46.
Du
Y
,
Shi
S
,
Shu
C
,
He
Y
,
Xu
W
,
Wu
D
, et al
.
Discovery of novel EGFR-PROTACs capable of degradation of multiple EGFR-mutated proteins
.
Eur J Med Chem
.
2024
;
272
:
116489
.
47.
Pinto
E
,
Pelizzaro
F
,
Cardin
R
,
Battistel
M
,
Palano
G
,
Bertellini
F
, et al
.
HIF-1α and VEGF as prognostic biomarkers in hepatocellular carcinoma patients treated with transarterial chemoembolization
.
Dig Liver Dis
.
2024
;
56
(
5
):
872
9
.
48.
Kwon
JH
,
Lee
J
,
Kim
J
,
Jo
YH
,
Kirchner
VA
,
Kim
N
, et al
.
HIF-1α regulates A2B adenosine receptor expression in liver cancer cells
.
Exp Ther Med
.
2019
;
18
(
6
):
4231
40
.
49.
Seo
J
,
Jeong
D-W
,
Park
J-W
,
Lee
KW
,
Fukuda
J
,
Chun
YS
.
Fatty-acid-induced FABP5/HIF-1 reprograms lipid metabolism and enhances the proliferation of liver cancer cells
.
Commun Biol
.
2020
;
3
(
1
):
638
.
50.
Meng
J
,
Wang
L
,
Hou
J
,
Yang
X
,
Lin
K
,
Nan
H
, et al
.
CCL23 suppresses liver cancer progression through the CCR1/AKT/ESR1 feedback loop
.
Cancer Sci
.
2021
;
112
(
8
):
3099
110
.
51.
Razaghi
A
,
Björnstedt
M
.
Exploring selenoprotein P in liver cancer: advanced statistical analysis and machine learning approaches
.
Cancers
.
2024
;
16
(
13
):
2382
.
52.
Wang
Y
,
Chen
Z
.
Mutation detection and molecular targeted tumor therapies
.
STEMedicine
.
2020
;
1
(
1
):
e11
.
53.
Yin
Y
,
Sun
M
,
Zhan
X
,
Wu
C
,
Geng
P
,
Sun
X
, et al
.
EGFR signaling confers resistance to BET inhibition in hepatocellular carcinoma through stabilizing oncogenic MYC
.
J Exp Clin Cancer Res
.
2019
;
38
(
1
):
83
.
54.
Zou
M
,
Zheng
Z
,
Xiahou
Z
,
Cao
J
.
Prediction of potential targets and toxicological insights of Astragalus in liver cancer based on network pharmacology: integrating systems biology, drug interaction networks, and toxicological perspectives
.
Environ Toxicol
.
2024
.
55.
Chen
J
,
Li
X
,
Cheng
Q
,
Ning
D
,
Ma
J
,
Zhang
ZP
, et al
.
Effects of cyclin D1 gene silencing on cell proliferation, cell cycle, and apoptosis of hepatocellular carcinoma cells
.
J Cell Biochem
.
2018
;
119
(
2
):
2368
80
.
56.
Liu
YM
,
Li
XQ
,
Zhang
XR
,
Chen
YY
,
Liu
YP
,
Zhang
HQ
, et al
.
Uncovering the key pharmacodynamic material basis and possible molecular mechanism of extract of Epimedium against liver cancer through a comprehensive investigation
.
J Ethnopharmacol
.
2023
;
317
(
1
):
116765
.
57.
Lai
XY
,
Xia
WB
,
Wei
J
,
Ding
X
.
Therapeutic effect of Astragalus polysaccharides on hepatocellular carcinoma H22-bearing mice
.
Dose Response
.
2017
;
15
(
1
):
1559325816685182
.
58.
Johnstone
RW
,
Ruefli
AA
,
Lowe
SW
.
Apoptosis: a link between cancer genetics and chemotherapy
.
Cell
.
2002
;
108
(
2
):
153
64
.
59.
del Peso
L
,
González-García
M
,
Page
C
,
Herrera
R
,
Nuñez
G
.
Interleukin-3-Induced phosphorylation of BAD through the protein kinase akt
.
Science
.
1997
;
278
(
5338
):
687
9
.
60.
Kitada
S
,
Krajewska
M
,
Zhang
X
,
Scudiero
D
,
Zapata
JM
,
Wang
HG
, et al
.
Expression and location of pro-apoptotic Bcl-2 family protein BAD in normal human tissues and tumor cell lines
.
Am J Pathol
.
1998
;
152
(
1
):
51
61
.
61.
Lu
H
,
Hu
J
,
Li
J
,
Lu
W
,
Deng
X
,
Wang
X
.
miR-328-3p overexpression attenuates the malignant proliferation and invasion of liver cancer via targeting endoplasmic reticulum metallo protease 1 to inhibit AKT phosphorylation
.
Ann Transl Med
.
2020
;
8
(
12
):
754
.
62.
Deng
BY
,
Liu
F
,
Luo
LM
,
Wei
Y
,
Li
B
,
Yang
H
.
CASP 3 genetic polymorphisms and risk of Hepatocellular carcinoma: a case-control study in a Chinese population
.
Tumour Biol
.
2016
;
37
(
7
):
8985
91
.
63.
Zhang
S
,
Xiao
QY
,
Shi
ZQ
,
Yu
G
,
Ma
XP
,
Chen
H
, et al
.
Caspase polymorphisms and prognosis of hepatocellular carcinoma
.
PLoS One
.
2017
;
12
(
4
):
e0176802
.
64.
Jang
JW
,
Song
Y
,
Kim
SH
,
Kim
JS
,
Kim
KM
,
Choi
EK
, et al
.
CD133 confers cancer stem-like cell properties by stabilizing EGFR-AKT signaling in hepatocellular carcinoma
.
Cancer Lett
.
2017
;
389
(
1
):
1
10
.
You do not currently have access to this content.